表紙
市場調查報告書

H+ Transporting Two Sector ATPase:開發中產品分析

H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 372679
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
H+ Transporting Two Sector ATPase:開發中產品分析 H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 47 Pages
簡介

本報告提供以H+ Transporting Two Sector ATPase為標的的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

H+ Transporting Two Sector ATPase 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發作的企業

  • Johnson & Johnson
  • Lycera Corp.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2273TDB

Summary

According to the recently published report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020'; H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na+) gradient, which drives rotation of membranous F0 motor components.

The report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020' outlays comprehensive information on the H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Phase I stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease and Immunology which include indications Tuberculosis, Leprosy, Plaque Psoriasis (Psoriasis Vulgaris) and Pulmonary Tuberculosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
  • The report reviews H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics and enlists all their major and minor projects
  • The report assesses H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Overview
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Companies Involved in Therapeutics Development
  • Johnson & Johnson
  • Lycera Corp
  • Shanghai Jiatan Pharmaceutical Technology Co Ltd
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Drug Profiles
  • bedaquiline fumarate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LYC-30937 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ATP Synthase for Tuberculosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WX-081 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Dormant Products
  • H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 16, 2019: World Health Organization recommends the use of Bedaquiline-containing treatment regimens for all drug-resistant Tuberculosis patients
  • Dec 12, 2019: CHMP recommended extension of indication for Sirturo
  • Aug 09, 2019: Janssen Announces U.S. FDA Accelerated Approval for SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
  • Jun 28, 2019: New method reveals how well TB antibiotics reach their targets
  • Apr 25, 2019: MSF: Johnson & Johnson should make TB drug available for all at $1/day
  • Aug 17, 2018: World Health Organization recommends the use of bedaquiline in all conventional multidrug-resistant tuberculosis treatment regimens
  • Jul 04, 2018: New drugs to treat top infectious disease killer a possibility with Otago discovery
  • Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate
  • Dec 07, 2016: Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
  • Dec 01, 2016: China Food And Drug Administration Approves Sirturo (Bedaquiline) For Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
  • Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis
  • Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
  • Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn's and Colitis Organization (ECCO)
  • Aug 24, 2015: Janssen's SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis
  • Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Johnson & Johnson, H1 2020
  • Pipeline by Lycera Corp, H1 2020
  • Pipeline by Shanghai Jiatan Pharmaceutical Technology Co Ltd, H1 2020
  • Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020